NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults
June 01, 2021 02:00 ET
|
NMD Pharma
PRESS RELEASE NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults Aarhus, Denmark, 1 June 2021 – NMD Pharma A/S,...
NMD Pharma Moves Corporate Headquarters to INCUBA to Support Future Growth
November 30, 2020 01:00 ET
|
NMD Pharma
NMD Pharma Moves Corporate Headquarters to INCUBA to Support Future Growth Aarhus, Denmark, 30 November 2020 – NMD Pharma A/S, a biotech company leading in the development of novel therapeutics for...
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
October 06, 2020 07:00 ET
|
NMD Pharma
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 6 October 2020 – NMD Pharma A/S, a biotech company...
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
October 06, 2020 01:00 ET
|
NMD Pharma
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 6 October 2020 – NMD Pharma A/S, a biotech company...
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
July 14, 2020 07:00 ET
|
NMD Pharma
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech...
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
July 14, 2020 02:00 ET
|
NMD Pharma
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech...